Abstract
The development of antagonists of growth hormone (GH) - releasing hormone (GH-RH) is reviewed. GH-RH antagonists bind with a high affinity to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The main applications of GH-RH antagonists would be for tumor therapy. The antitumor effects of GH-RH antagonists are exerted in part indirectly through the inhibition of the secretion of pituitary GH and the reduction in the levels of hepatic insulin like growth factor (IGF-I). However, principal effects of the GH-RH antagonists are exerted directly on tumors. Antagonists of GH-RH inhibit the proliferation of various cancer cell lines in vitro and suppress in vivo the levels and the expression of mRNA for IGF-I and IGF-II in tumors. In many human cancers, the effects of GH-RH antagonists appear to be due to the blockade of the action of tumoral GH-RH. GH-RH ligand is present in various human cancers indicating that it may be an autocrine/paracrine growth factor. Splice variants (SVs) of GH-RH receptors and pituitary type of GH-RH receptors that might mediate effects of tumoral GH-RH and of GH-RH antagonists were demonstrated in many human cancers. This suggests the presence of a stimulatory loop based on GH-RH and SVs or pituitary type of GHRH receptors in diverse tumors. It was shown that GH-RH antagonists inhibited the growth of various human cancer lines xenografted into nude mice including mammary, ovarian, endometrial and prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, renal, pancreatic, gastric and colorectal carcinomas, malignant gliomas, osteosarcomas and Non- Hodgkins lymphomas. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.
Keywords: GH-RH, GH-RH receptors, receptor splice variants, inhibition of pituitary GH release, antitumor activity, cancer therapy
Combinatorial Chemistry & High Throughput Screening
Title: Antagonists of Growth Hormone-Releasing Hormone in Oncology
Volume: 9 Issue: 3
Author(s): Andrew V. Schally and Jozsef L. Varga
Affiliation:
Keywords: GH-RH, GH-RH receptors, receptor splice variants, inhibition of pituitary GH release, antitumor activity, cancer therapy
Abstract: The development of antagonists of growth hormone (GH) - releasing hormone (GH-RH) is reviewed. GH-RH antagonists bind with a high affinity to pituitary receptors for GH-RH and inhibit the release of GH in vitro and in vivo. The main applications of GH-RH antagonists would be for tumor therapy. The antitumor effects of GH-RH antagonists are exerted in part indirectly through the inhibition of the secretion of pituitary GH and the reduction in the levels of hepatic insulin like growth factor (IGF-I). However, principal effects of the GH-RH antagonists are exerted directly on tumors. Antagonists of GH-RH inhibit the proliferation of various cancer cell lines in vitro and suppress in vivo the levels and the expression of mRNA for IGF-I and IGF-II in tumors. In many human cancers, the effects of GH-RH antagonists appear to be due to the blockade of the action of tumoral GH-RH. GH-RH ligand is present in various human cancers indicating that it may be an autocrine/paracrine growth factor. Splice variants (SVs) of GH-RH receptors and pituitary type of GH-RH receptors that might mediate effects of tumoral GH-RH and of GH-RH antagonists were demonstrated in many human cancers. This suggests the presence of a stimulatory loop based on GH-RH and SVs or pituitary type of GHRH receptors in diverse tumors. It was shown that GH-RH antagonists inhibited the growth of various human cancer lines xenografted into nude mice including mammary, ovarian, endometrial and prostate cancers, small cell lung carcinomas (SCLC) and non-SCLC, renal, pancreatic, gastric and colorectal carcinomas, malignant gliomas, osteosarcomas and Non- Hodgkins lymphomas. Further development of GH-RH antagonists should lead to potential therapeutic agents for various cancers.
Export Options
About this article
Cite this article as:
Schally V. Andrew and Varga L. Jozsef, Antagonists of Growth Hormone-Releasing Hormone in Oncology, Combinatorial Chemistry & High Throughput Screening 2006; 9 (3) . https://dx.doi.org/10.2174/138620706776055449
DOI https://dx.doi.org/10.2174/138620706776055449 |
Print ISSN 1386-2073 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5402 |
Call for Papers in Thematic Issues
Artificial Intelligence Methods for Biomedical, Biochemical and Bioinformatics Problems
Recently, a large number of technologies based on artificial intelligence have been developed and applied to solve a diverse range of problems in the areas of biomedical, biochemical and bioinformatics problems. By utilizing powerful computing resources and massive amounts of data, methods based on artificial intelligence can significantly improve the ...read more
Eco-friendly Agents for Biological Control of Pathogenic Diseases
The discovery of an alternative biological approach to disease management includes work on medicinal products derived from natural sources as a starting point for the development of eco-friendly agents for these diseases and the injuries they cause, as well as reducing human contact with hazardous chemicals and their residues. We ...read more
Emerging trends in diseases mechanisms, noble drug targets and therapeutic strategies: focus on immunological and inflammatory disorders
Recently infectious and inflammatory diseases have been a key concern worldwide due to tremendous morbidity and mortality world Wide. Recent, nCOVID-9 pandemic is a good example for the emerging infectious disease outbreak. The world is facing many emerging and re-emerging diseases out breaks at present however, there is huge lack ...read more
Exploring Spectral Graph Theory in Combinatorial Chemistry
Scope of the Thematic Issue: Combinatorial chemistry involves the synthesis and analysis of a large number of diverse compounds simultaneously. Traditional methods rely on brute force experimentation, which can be time-consuming and resource-intensive. Spectral Graph Theory, a branch of mathematics dealing with the properties of graphs in relation to the ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Dendritic Cell Immunotherapy for Malignant Gliomas
Reviews on Recent Clinical Trials Targeting mTOR: Evaluating the Therapeutic Potential of Resveratrol for Cancer Treatment
Anti-Cancer Agents in Medicinal Chemistry Herpes Simplex Virus Type 1 Amplicons and their Hybrid Virus Partners, EBV, AAV, and Retrovirus
Current Gene Therapy Cyclooxygenase-2: Potential Role in Regulation of Drug Efflux and Multidrug Resistance Phenotype
Current Pharmaceutical Design Hitting the Golden TORget: Curcumin’s Effects on mTOR Signaling
Anti-Cancer Agents in Medicinal Chemistry The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases
Anti-Infective Agents in Medicinal Chemistry Targeting Mevalonate Pathway in Cancer Treatment: Repurposing of Statins
Recent Patents on Anti-Cancer Drug Discovery A Review on Medical Image Registration as an Optimization Problem
Current Medical Imaging Apoptosis Signaling Pathways in Anticancer Therapy
Current Cancer Therapy Reviews Development of <sup>18</sup>F-Labeled PET Probes for Imaging Cell Proliferation
Current Topics in Medicinal Chemistry Development of RGD-Based Radiotracers for Tumor Imaging and Therapy: Translating from Bench to Bedside
Current Molecular Medicine HIV-1 Proteins, Tat and gp120, Target the Developing Dopamine System
Current HIV Research Phenolic Compounds as Nutraceuticals or Functional Food Ingredients
Current Pharmaceutical Design Can γH2AX be Used to Personalise Cancer Treatment?
Current Molecular Medicine Bispecific Antibodies: An Innovative Arsenal to Hunt, Grab and Destroy Cancer Cells
Current Pharmaceutical Biotechnology Herpes Simplex Viruses in Antiviral Drug Discovery
Current Pharmaceutical Design Influence of Aldo-keto Reductase 1C3 in Prostate Cancer - A Mini Review
Current Cancer Drug Targets Nitrosative Stress as a Mediator of Apoptosis: Implications for Cancer Therapy
Current Pharmaceutical Design Recent Advances on Small-Molecule Survivin Inhibitors
Current Medicinal Chemistry Neurorescue Activity, APP Regulation and Amyloid-β Peptide Reduction by Novel Multi-Functional Brain Permeable Iron- Chelating- Antioxidants,M-30 and Green Tea Polyphenol, EGCG
Current Alzheimer Research